TScan Therapeutics

TScan is a fully integrated clinical-stage biotech company focused on developing a robust pipeline of TCR-T therapies for the treatment of patients with cancer

[TScan Therapeutics @TScan_Tx]

In recognition of #NationalCancerSurvivorMonth, we honor the strength and resilience of cancer survivors and acknowledge the caregivers, families, researchers, and clinicians who support them. We are proud to work toward a future with more survivorship stories.

[TScan Therapeutics @TScan_Tx]

Today we announced our agreement with Cellares to evaluate automated manufacturing of TSC-101 for patients with heme malignancies. Read more here: https://t.co/bkRvUAMtGA

[TScan Therapeutics @TScan_Tx]

TScan launched our new corporate website!

The updated site reflects how far we’ve come, with a sharper, more dynamic experience that matches the momentum behind our science and programs.

Take a look: https://t.co/sIpj9MprIU

#Tcells #CellTherapy

[TScan Therapeutics @TScan_Tx]

This month, #TScanners came together as TSpinners to ride for a cause that's close to our hearts! We raised over $23,000 participating in Cycle for Survival, the official rare cancer fundraising program of MSK Cancer Center #CycleForSurvival #RareCancer #MSK

[TScan Therapeutics @TScan_Tx]

Today we announced that the Company will participate in a fireside chat at the @HCWCO 3rd Annual Cell Therapy Virtual Conference on Tuesday, February 25 at 10:00 a.m. ET. Learn more: https://t.co/6F2rF5WKSg #CellTherapy #TCells

[TScan Therapeutics @TScan_Tx]

Honoring women and girls in science today and every day! At TScan, we celebrate the talented women driving progress in science. #WomenInScience #GirlsInSTEM

[TScan Therapeutics @TScan_Tx]

On #WorldCancerDay, we reflect on our Mission Wall and the submissions from our #TScanners that tell a personal story of how cancer has impacted their lives, reminding us that we are #UnitedByUnique. More about our programs targeting various cancers: https://t.co/kWxirHXq4y

[TScan Therapeutics @TScan_Tx]

We look forward to being in San Francisco next week during #JPM2025! Connect with us to learn more about our recent progress and exciting plans for 2025. #CellTherapy #TCells #Biotech

[TScan Therapeutics @TScan_Tx]

Today we announced that we have entered into a $30 million registered direct offering at a 37% premium with Lynx1 Capital Management and an investment fund advised by Lynx1. Read the press release to learn more: https://t.co/DAuql68xI3 #CellTherapy #Biotech

[TScan Therapeutics @TScan_Tx]

Today we announced updated data from the ongoing ALLOHA™ Phase 1 heme trial being presented in an oral session at #ASH24. Read the press release to learn more and join our virtual KOL event tomorrow where we will discuss these data. https://t.co/tEnLsmjQbZ

[TScan Therapeutics @TScan_Tx]

We’ll be presenting preliminary results from the ALLOHA™ Phase 1 trial of TSC-100 and TSC-101 in #AML, #ALL, and #MDS at #ASH24. Join our virtual KOL event on 12/10 at 8am ET, where we'll discuss the data presented at ASH and more! Register here: https://t.co/FYqcHH3kqt

[TScan Therapeutics @TScan_Tx]

For the third year, we’re one of @BostonGlobe’s 2024 Top Places to Work! This achievement reflects our commitment to creating an inclusive environment and dedication to improving the lives of patients with #Cancer. Thank you to our team! https://t.co/PFURh0zpFD

[TScan Therapeutics @TScan_Tx]

Yesterday we announced we’ll host a virtual KOL event on 12/10 at 8am ET to discuss data from the ALLOHA™ Phase 1 trial presented at #ASH24, our clinical development strategy for the heme program and an update on the PLEXI-T™ Phase 1 solid tumor trial. https://t.co/t9TnPegvN7

[TScan Therapeutics @TScan_Tx]

TScan is proud to be named to the 2024 @TopWorkplaces list for Appreciation, Employee Well-Being, and Professional Development! This recognition is thanks to invaluable feedback from #TScanners. We’re grateful for this honor and the people who made it possible. #TopWorkplaces

[TScan Therapeutics @TScan_Tx]

Today we reported third quarter financial results and provided a corporate update. Read the press release to learn more about our recent accomplishments and upcoming anticipated milestones: https://t.co/UM3YjIrnNP #CellTherapy #UnleashImmunity #TCells

[TScan Therapeutics @TScan_Tx]

Happy #NationalSTEMDay! At #TScan, we know that STEM is a driving force behind innovation in biotech. To celebrate and inspire the next generation of STEM talent, we heard from some of our #TScanners on the importance of STEM and what it means to them to be part of this field.

[TScan Therapeutics @TScan_Tx]

Today we announced that data from the ALLOHA™ Phase 1 trial will be featured in an oral presentation at #ASH24 on 12/9. Join our virtual KOL event on 12/10 at 8:00 a.m. ET where we'll discuss the data presented at the meeting. Learn more: https://t.co/NoXVABv2TC

[TScan Therapeutics @TScan_Tx]

We had the incredible opportunity to hear from some of our TScanners in our latest installment of #CareerJourneys, as they shared their unique paths and experiences that led them to #TScan! Every journey is valuable, and it was inspiring to learn from their stories.

[TScan Therapeutics @TScan_Tx]

Thank you @NatureBiotech for featuring us in an article and speaking with our CEO, Gavin MacBeath, PhD, about our approach to provide customized multiplex TCR-T therapies for a variety of #Cancers. Read the article: https://t.co/yN8qAQfcRH #SolidTumors #CellTherapy

[TScan Therapeutics @TScan_Tx]

Today we announced the acceptance of three abstracts for poster presentation at the upcoming @sitcancer 39th Annual Meeting being held November 6 - 10 in Houston, TX and virtually. Learn more: https://t.co/n0jXpMCQV5 #SITC24 #CellTherapy